Gyre Therapeutics, Inc. Accounts Receivable, Credit Loss Expense (Reversal)
Gyre Therapeutics, Inc. (GYRE) reported Accounts Receivable, Credit Loss Expense (Reversal) of $200.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-30.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ProvisionForDoubtfulAccounts · last filed 2023-10-26
- Gyre Therapeutics, Inc. accounts receivable, credit loss expense (reversal) for the quarter ending 2022-12-31 was $0.00.
- Gyre Therapeutics, Inc. accounts receivable, credit loss expense (reversal) for the quarter ending 2022-09-30 was $0.00.
- Gyre Therapeutics, Inc. accounts receivable, credit loss expense (reversal) for the quarter ending 2022-06-30 was $0.00.
- Gyre Therapeutics, Inc. accounts receivable, credit loss expense (reversal) for the quarter ending 2022-03-31 was $200.00K.
- Gyre Therapeutics, Inc. accounts receivable, credit loss expense (reversal) for fiscal 2022 was $200.00K.
| Period end | Accounts Receivable, Credit Loss Expense (Reversal) 3 month | Accounts Receivable, Credit Loss Expense (Reversal) 6 month | Accounts Receivable, Credit Loss Expense (Reversal) 9 month | Accounts Receivable, Credit Loss Expense (Reversal) 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $0.00 derived: sum of 2 quarters · filed 2023-10-26 | $0.00 derived: sum of 3 quarters · filed 2023-10-26 | $200.00K 10-K · filed 2023-03-30 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26 | $0.00 derived: sum of 2 quarters · filed 2023-10-26 | $200.00K 10-Q · filed 2023-10-26 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $200.00K 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $200.00K 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |